Introduction {#sec1}
============

Canonical cyclic dinucleotides (CDNs) that possess two 3′--5′ internucleotide linkages, such as cyclic diguanosine monophosphate (c-di-GMP, **1**) and cyclic diadenosine monophosphate (c-di-AMP, **2**), are ubiquitous second messenger molecules in bacteria ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). The CDNs have been reported to participate in a myriad of signaling pathways in bacteria for the past three decades.^[@ref1]−[@ref3]^ In 2013, cyclic guanosine monophosphate--adenosine monophosphate (cGAMP) was reported as the first metazoan second messenger produced by DNA-activated cGAMP synthase (cGAS).^[@ref4],[@ref5]^ In contrast to the bacterial CDNs, the metazoan cGAMP was identified to have one 2′--5′ and one 3′--5′ internucleotide linkage, \[G(2′--5′)pA(3′--5′)p\] (2′3′-cGAMP, **3**).^[@ref6]−[@ref8]^ The second messenger **3** induces secretion of type I interferons and activates the immune system; this observation has led to intense interest in CDNs as vaccine adjuvants or immunotherapeutics.^[@ref9],[@ref10]^ In the field of therapeutics, CDN bisphosphorothioates (CDNSSs) are of particular interest, because the phosphorothioate linkages in CDNSSs confer increased resistance to hydrolysis by phosphodiesterases.^[@ref11]^ In addition to their increased hydrolytic stability, CDNSSs are more lipophilic and cell permeable compared to CDNs, thereby offering improved cell activities.^[@ref11]−[@ref15]^

![Structures of c-di-GMP, c-di-AMP, and 2′3′-cGAMP.](ao0c01942_0001){#fig1}

Chemical and biocatalytic syntheses of CDNSSs provide up to four bisphosphorothioate diastereomers depending upon the stereospecificity of the syntheses and the molecular symmetry of CDNSSs.^[@ref11],[@ref16]−[@ref18]^ Typically, bisphosphorothioate diastereomers are either chromatographically separated and characterized individually^[@ref12],[@ref14],[@ref15],[@ref19]^ or evaluated as a diastereomeric mixture without further purification.^[@ref11],[@ref13]^ Stereochemistry assignment of the three diastereomers of c-di-GMP bisphosphorothioate, *R*~p~*R*~p~, *R*~p~*S*~p~, and *S*~p~*S*~p~, was reported based on their retention times on reverse-phase high-performance liquid chromatography (HPLC) and ^31^P NMR chemical shifts.^[@ref19]^ This method was also applied in assigning the stereochemistry of 2′3′-CDNSS diastereomers by another group, who confirmed the stereochemistry of a 2′3′-CDNSS diastereomer via an X-ray single-crystal structure.^[@ref12],[@ref20]^ However, retention times on reverse-phase HPLC and ^31^P NMR chemical shifts of CDNSSs are often too close from one to another, making unambiguous stereochemistry assignments difficult. In addition, this method relies on relative values of retention times on reverse-phase HPLC and ^31^P NMR chemical shifts of the bisphosphorothioate diastereomers and thereby requires a full set of three or four diastereomers for the stereochemistry assignment. Occasionally, however, chemical syntheses fail to provide all of the possible bisphosphorothioate diastereomers due to stereoselective chemical steps and difficulty in purification.^[@ref13]^ Moreover, biocatalytic syntheses of CDNSSs do not provide all diastereomers because of the intrinsic specificity of the enzymes.^[@ref11],[@ref18],[@ref21]^ Therefore, development of a novel method that enables the unequivocal assignment of the stereochemistry of a given CDNSS would be highly desirable. Herein, a novel unambiguous method of stereochemistry determination of 2′3′-cGAMP bisphosphorothioate (2′3′-cG^S^A^S^MP, **4**)^[@ref21],[@ref22]^ employing snake venom phosphodiesterase (svPDE) and nP1 is reported. In addition, the stereospecificity as well as regiospecificity of svPDE and nP1 toward **4** is discussed.

Results and Discussion {#sec2}
======================

Determination of the absolute stereochemistry of phosphorothioate centers utilizing various enzymes has been well established for linear dinucleotide phosphorothioates (DNSs) in the literature.^[@ref23]−[@ref26]^ Two of the most widely used enzymes are snake venom phosphodiesterase (svPDE) and nuclease P1 (nP1). SvPDE cleaves 2′--5′ and 3′--5′ phosphodiester bonds and hydrolyzes *R*~p~ phosphorothioates stereospecifically. On the other hand, nP1 specifically hydrolyzes 3′--5′ phosphodiester bonds and *S*~p~ phosphorothioates.^[@ref27]^ These biocatalytic transformations have been successfully applied in determining the absolute stereochemistry of numerous linear DNSs for decades.^[@ref28]−[@ref31]^ However, enzymatic determination of the stereochemistry of phosphorothioate centers in CDNSS has not been reported in the literature. Application of hydrolytic enzymes to CDNSSs has been limited to demonstrating their resistance to enzymatic hydrolysis and higher cellular activities compared to CDNs.^[@ref12],[@ref13]^ In fact, application of biocatalysis to CDNSSs in the context of the relative hydrolytic stability between *R*~p~ and *S*~p~, let alone the stereochemistry determination, has not been reported. Given that svPDE and nP1 differentially hydrolyze *R*~p~ and *S*~p~ stereocenters in linear DNSs, we hypothesized that the enzymes might hydrolyze the phosphorothioate centers in CDNSSs regioselectively and stereoselectively, offering an opportunity to develop a novel method of stereochemistry determination of CDNSSs.

To test the hypothesis, four diastereomers of **4** (**4a**, **4b**, **4c**, and **4d**, whose retention times on HPLC are 6.0, 5.4, 5.3, and 4.9 min, respectively; 50 pmol each) were subjected to svPDE and nP1 hydrolysis conditions ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). Interestingly, the four diastereomers displayed distinct LC profiles when they were incubated with the enzymes. Diastereomer **4a** was hydrolyzed to the monophosphorothioates (MPSs) and the monophosphates (MPs) by svPDE and was resistant to nP1 ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A). On the other hand, **4b** was hydrolyzed to two different sets of linear DNSs by either svPDE or nP1 ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B). While **4c** was resistant to both enzymes, **4d** was hydrolyzed to linear DNSs by nP1 and was resistant to svPDE ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C,D).

![Enzymatic hydrolysis of 2′3′-cG^S^A^S^MP with svPDE and nP1. LC profiles of **4a** (A), **4b** (B), **4c** (C), and **4d** (D) incubated with svPDE and nP1. SvPDE conditions: 2′3′-cG^S^A^S^MP (0.05 μmol), svPDE (0.008 unit), pH 8.5 buffer solution (0.2 mL), 37 °C, 20 h; nP1 conditions: 2′3′-cG^S^A^S^MP (0.05 μmol), nP1 (11 unit), pH 7.0 buffer solution (0.2 mL), 37 °C, 20 h. The liquid chromatography (LC) spectra of the starting materials, the reactions after incubation with svPDE, and the reactions after incubation with nP1 are in green, red, and blue, respectively. A fixed amount of 2′3′-isopropylideneadenosine was added to each LC-mass spectrometry (LCMS) sample as a reference (ref). The minor peak on the LC spectrum of **4c** incubated with nP1 was from an inseparable impurity in the sample. GMP = guanosine monophosphate, GMPS = guanosine monophosphorothioate, AMP = adenosine monophosphate, AMPS = adenosine monophosphorothioate, MP = monophosphate, and MPS = monophosphorothioate.](ao0c01942_0002){#fig2}

Next, the reactions were scaled up for full characterization of the products to decipher the distinct LC patterns. Hydrolysis products of **4b** were studied first since **4b** was hydrolyzed by both svPDE and nP1, which would offer an insight into the stereospecificity of the enzymes. Incubation of **4b** with svPDE and nP1 afforded the distinct linear DNSs **5** and **6**, respectively ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). The structure of **5** was unambiguously determined to be 5′-pA^S^(3′--5′)pG^S^ via two-dimensional (2-D) NMR experiments, displaying correlations from H^3^′^A^ and H^5^′^G^ to P^(3^′^--5^′^)^ in ^1^H--^31^P heteronuclear multiple bond correlation (HMBC) ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}). In the same manner, the structure of **6** was determined to be 5′-pG^S^(2′--5′)pA^S^ via 2-D NMR experiments. Formation of linear DNSs **5** and **6** indicates that the 2′--5′ phosphorothioate bond of **4b** was hydrolyzed by svPDE, while the 3′--5′ phosphorothioate bond was hydrolyzed by nP1. Linear DNSs **5** and **6** were then incubated with the other enzyme, **5** with nP1 and **6** with svPDE, to determine the phosphorothioate stereochemistry. Both **5** and **6** were hydrolyzed to GMP/GMPS and AMP/AMPS by nP1 and svPDE, respectively, which confirmed the stereochemistry of **5** and **6** to be (3′--5′)*S*~P~ and (2′--5′)*R*~P~, respectively ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Taken together, the stereochemistry of **4b** was determined to be (2′--5′)*R*~P~(3′--5′)*S*~P~, which indicates that (2′--5′)*R*~P~ in **4b** was hydrolyzed by svPDE to afford **5** and (3′--5′)*S*~P~ in **4b** was hydrolyzed by nP1 to afford **6**.

![^1^H--^31^P HMBC correlations of **5** and **6**.](ao0c01942_0003){#fig3}

![Hydrolytic Products of **4b** Treated with svPDE and nP1,\
svPDE, pH 8.5 buffer solution, 37 °C.\
nP1, pH 7.0 buffer solution, 37 °C.](ao0c01942_0004){#sch1}

Biocatalytic hydrolysis products of **4a** and **4d** by svPDE and nP1 were characterized next. The hydrolysis products of **4a** by svPDE were confirmed to be a mixture of mononucleotides **7** and **8** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). The outcome indicates that svPDE hydrolyzed either the (2′--5′)*R*~P~ or the (3′--5′)*R*~P~ phosphorothioate linkage in **4a** first and then subsequently rapidly hydrolyzed the linear DNS product to the mononucleotides. The resistance of **4a** to nP1 also supports the assignment of the 3′--5′ phosphorothioate of **4a** to be *R*~P~. Taken together, the stereochemistry of **4a** was determined to be (2′--5′)*R*~P~(3′--5′)*R*~P~. Incubation of **4d** with nP1 afforded linear DNS **9**, whose 5′-pG^S^(2′--5′)pA^S^ structure was confirmed via 2-D NMR experiments, indicating that (3′--5′)*S*~P~ in **4d** was hydrolyzed by nP1. While **6**, the biocatalysis product of **4b** by nP1, was hydrolyzed by svPDE, **9** was resistant to svPDE. The results confirmed that the stereochemistry of **9** is (2′--5′)*S*~P~ and that of **4d** is (2′--5′)*S*~P~(3′--5′)*S*~P~.

![Hydrolytic Products of **4a** and **4d** Treated with svPDE and nP1,\
svPDE, pH 8.5 buffer solution, 37 °C.\
nP1, pH 7.0 buffer solution, 37 °C.](ao0c01942_0005){#sch2}

Structural determination of the hydrolysis products of **4a**, **4b**, and **4d** demonstrated that (2′--5′)*R*~P~ and (3′--5′)*S*~P~ of **4** are hydrolyzed by svPDE and nP1, respectively. Diastereomer **4c** was resistant to both enzymes ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C), which confirms that the stereochemistry of **4c** is (2′--5′)*S*~P~(3′--5′)*R*~P~. The results also indicate that the 3′--5′ phosphorothioate linkage and the 2′--5′ phosphorothioate linkage in **4** are resistant to svPDE and nP1, respectively, regardless of the phosphorothioate stereochemistry. Given the regiospecificity of svPDE, when **4a** was incubated with svPDE, the (2′--5′)*R*~P~ phosphorothioate linkage was hydrolyzed first to afford 5′-pA^S^(3′--5′)pG^S^, and then, the (3′--5′)*R*~P~ phosphorothioate of the resultant linear DNS was subsequently hydrolyzed to afford the mononucleotides.

In the course of determining the phosphorothioate stereochemistry of **4a**--**4d**, the regiospecificity as well as stereospecificity of both svPDE and nP1 toward **4** has been revealed ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). As seen with linear DNSs, svPDE and nP1 preferentially hydrolyzed *R*~P~ and *S*~P~ phosphorothioate linkages in **4**, respectively. It is interesting to note that svPDE hydrolyzes only (2′--5′)*R*~P~ phosphorothioate linkages in **4**, whereas the enzyme hydrolyzes both (2′--5′)*R*~P~ and (3′--5′)*R*~P~ phosphorothioate linkages in linear DNS. On the other hand, nP1 hydrolyzes only (3′--5′)*S*~P~ phosphorothioate linkages in both **4** and linear DNS. Overall, the assignment of the **4a**--**4d** phosphorothioate stereochemistry completely matches the stereospecificity and the regiospecificity of the svPDE and nP1 biocatalysis as well as the hydrolysis patterns ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). This novel biocatalysis was then applied to ADU-S100 (*R*~P~*R*~P~ 2′3′-c-di-AMPSS), whose stereochemistry had been confirmed by an X-ray single-crystal structure.^[@ref20]^ ADU-S100 was hydrolyzed to a mixture of adenosine monophosphorothioate and adenosine monophosphate by svPDE and was resistant to nP1, which is consistent with the (2′--5′)*R*~P~/(3′--5′)*R*~P~ stereochemistry of ADU-S100.

###### Stereospecific and Regiospecific Hydrolysis of 2′3′-cG^S^A^S^MP (**4**) and Linear DNS by svPDE and nP1

                     svPDE                           nP1
  ------------------ ------------------------------- ----------------
  2′3′-cG^S^A^S^MP   (2′--5′)*R*~P~                  (3′--5′)*S*~P~
  linear DNS         (2′--5′)*R*~P~/(3′--5′)*R*~P~   (3′--5′)*S*~P~

###### Stereochemistry Determination of 2′3′-cG^S^A^S^MPs (**4**) via Biocatalysis

![](ao0c01942_0006){#fx1}

                        4a             4b             4c             4d
  --------------------- -------------- -------------- -------------- --------------
  (2′--5′)P/(3′--5′)P   *R*~P~*R*~P~   *R*~P~*S*~P~   *S*~P~*R*~P~   *S*~P~*S*~P~
  svPDE                 Mono-Nucs      linear DNS     resistant      resistant
  nP1                   resistant      linear DNS     resistant      linear DNS

Conclusions {#sec3}
===========

A novel method of stereochemistry determination of 2′3′-cG^S^A^S^MP (**4**) via svPDE and nP1 biocatalysis has been developed. This method unambiguously assigned the phosphorothioate stereochemistry of four diastereomers of **4** by analyzing distinct hydrolysis patterns of the diastereomers incubated with svPDE and nP1. Furthermore, the stereospecificity as well as regiospecificity of both svPDE and nP1 toward **4** has been delineated. This novel method was successfully applied to other 2′3′-CDNSSs for their stereochemistry determination.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

Commercial reagents were obtained from reputable suppliers and used as received. Reactions were monitored by LC/MS (100 mm × 3 mm 2.7 μm column; 1--98% MeCN/water + 100 mM triethylammonium acetate gradient over 12 min; 1.0 mL/min flow; electrospray ionization (ESI); negative ion mode; UV detection at 254 nm). The ^1^H, ^13^C, and ^31^P NMR spectra were recorded on a 500 MHz, a 151 MHz, and a 202 MHz Varian spectrometer, respectively. Data for the NMR spectra are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, brs = broad singlet, d = doublet, t = triplet, dd = doublet of doublets, m = multiplet), coupling constant (Hz), and integration.

Analytical Biocatalysis with svPDE {#sec4.2}
----------------------------------

A 2′3′-cGAMP bisphosphorothioate triethylammonium salt diastereomer (10 mM in dimethyl sulfoxide (DMSO), 5 μL, 50 pmol) was placed in a vial and concentrated under high vacuum for 1 h. To the residue were added the buffer solution (100 mM Tris-HCl, pH 8.5, 15 mM MgCl~2~, 0.2 mL) and svPDE (Sigma-Aldrich P3243, a vial of ≥0.40 units in 1 mL of water, 40 μL). The reaction mixture was shaken at 37 °C for 20 h. The reaction was analyzed by LC/MS.

Analytical Biocatalysis with nP1 {#sec4.3}
--------------------------------

A 2′3′-cGAMP bisphosphorothioate triethylammonium salt diastereomer (10 mM in DMSO, 5 μL, 50 pmol) was placed in a vial and concentrated under high vacuum for 1 h. To the residue were added the buffer solution (100 mM Tris-HCl, pH 7, 1 mM ZnCl~2~, 0.2 mL) and nP1 (Sigma-Aldrich N8630, a vial of ≥250 units in 0.125 mL of water, 40 μL). The reaction mixture was shaken at 37 °C for 20 h. The reaction was analyzed by LC/MS.

*O*-{\[(2*R*,3*S*,4*R*,5*R*)-3-{\[(*S*)-{\[(2*R*,3*S*,4*R*,5*R*)-5-(2-Amino-6-oxo-1,6-dihydro-9*H*-purin-9-yl)-3,4-dihydroxytetrahydro-2-furanyl\]methoxy}(sulfanyl)phosphoryl\]oxy}-5-(6-amino-9*H-*purin-9-yl)-4-hydroxytetrahydro-2-furanyl\]methyl} Dihydrogen Phosphorothioate (**5**) {#sec4.4}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To a stirred solution of 2′3′-cGAMP bisphosphorothioate triethylammonium salt **4b** (22 mg, 0.020 mmol) in the buffer solution (100 mM Tris-HCl, pH 8.5, 15 mM MgCl~2~, 2 mL) was added svPDE (Sigma-Aldrich P3243, a vial of ≥0.40 units in 1 mL of water, 2 mL). The reaction mixture was shaken at 37 °C for 2 days, filtered, and purified by HPLC, eluting acetonitrile/water gradient with 100 mM triethylammonium acetate modifier to afford **5** triethylammonium salt (12 mg, 0.012 mmol, 63% yield) as a white solid. High-resolution mass spectrometry (HRMS) (ESI) calcd for (C~20~H~25~N~10~O~12~P~2~S~2~) \[M -- H\]^−^ 723.0570, found 723.0554. ^1^H NMR (500 MHz, D~2~O) δ 8.63 (s, 1H), 8.12 (s, 1H), 8.03 (s, 1H), 6.02 (d, *J* = 5.0 Hz, 1H), 5.81 (d, *J* = 5.5 Hz, 1H), 4.99 (m, 1H), 4.86 (m, 1H), 4.71 (m, 1H), 4.53 (brs, 2H), 4.34 (brs, 1H), 4.28--4.03 (m, 4H). ^13^C NMR (151 MHz, D~2~O) δ 158.79, 155.39, 153.85, 152.65, 151.44, 148.80, 140.03, 137.64, 118.49, 116.23, 87.27, 87.07, 83.57, 83.20, 75.03, 73.75, 73.61, 70.36, 65.24, 63.46. ^31^P NMR (202 MHz, D~2~O) δ 55.46, 43.38.

*O*-{\[(2*R*,3*R*,4*R*,5*R*)-5-(2-Amino-6-oxo-1,6-dihydro-9*H*-purin-9-yl)-4-{\[(*R*)-{\[(2*R*,3*S*,4*R*,5*R*)-5-(6-amino-9*H*-purin-9-yl)-3,4-dihydroxytetrahydro-2-furanyl\]methoxy}(sulfanyl)phosphoryl\]oxy}-3-hydroxytetrahydro-2-furanyl\]methyl} Dihydrogen Phosphorothioate (**6**) {#sec4.5}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To a stirred solution of 2′3′-cGAMP bisphosphorothioate triethylammonium salt **4b** (22 mg, 0.020 mmol) in the buffer solution (100 mM Tris-HCl, pH 7, 1 mM ZnCl~2~, 2 mL) was added nP1 (Sigma-Aldrich N8630, a vial of ≥250 units in 0.125 mL of water, 1.5 mL) over 2 days in three portions (0.5 mL x 3). The reaction mixture was shaken at 37 °C for 2 weeks, filtered, and purified by HPLC, eluting acetonitrile/water gradient with 100 mM triethylammonium acetate modifier to afford **6** triethylammonium salt (7.4 mg, 0.009 mmol, 45% yield) as a white solid. HRMS (ESI) calcd for (C~20~H~25~N~10~O~12~P~2~S~2~) \[M -- H\]^−^ 723.0570, found 723.0570. ^1^H NMR (500 MHz, D~2~O) δ 8.36 (s, 1H), 8.18 (s, 1H), 8.02 (s, 1H), 5.97 (brs, 1H), 5.93 (brs, 1H), 5.40 (m, 1H), 4.73 (m, 1H), 4.42--3.891 (m, 8H). ^13^C NMR (151 MHz, D~2~O) δ 158.08, 155.25, 153.31, 152.72, 151.23, 148.26, 139.43, 138.05, 118.26, 115.77, 87.79, 86.14, 83.43, 82.60, 77.52, 75.08, 70.09, 69.55, 63.96, 63.79. ^31^P NMR (202 MHz, D~2~O) δ 56.53, 42.81.

\[(2*R*,3*R*,4*R*,5*R*)-5-(2-Amino-6-oxo-1,6-dihydro-9*H*-purin-9-yl)-4-{\[(*S*)-{\[(2*R*,3*S*,4*R*,5*R*)-5-(6-amino-9*H*-purin-9-yl)-3,4-dihydroxytetrahydro-2-furanyl\]methoxy}(sulfanyl)phosphoryl\]oxy}-3-hydroxytetrahydro-2-furanyl\]methyl Dihydrogen Phosphate (**9**) {#sec4.6}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Prepared in analogy to that described for **6** in 78% yield. HRMS (ESI) calcd for (C~20~H~25~N~10~O~13~P~2~S) \[M -- H\]^−^ 707.0799, found 707.0807. ^1^H NMR (500 MHz, D~2~O) δ 8.28 (s, 1H), 8.15 (s, 1H), 7.97 (s, 1H), 5.98 (m, 1H), 5.93 (m, 1H), 5.25 (m, 1H), 4.65 (m, 1H), 4.43 (m, 1H), 4.36 (m, 1H), 4.27--3.92 (m, 6H). ^13^C NMR (151 MHz, D~2~O) δ 158.18, 155.24, 153.40, 152.70, 151.31, 148.34, 139.27, 138.03, 118.28, 115.86, 87.70, 86.34, 83.45, 82.74, 76.55, 74.82, 70.01, 69.55, 64.53, 63.84. ^31^P NMR (202 MHz, D~2~O) δ 55.57, 2.09.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsomega.0c01942](https://pubs.acs.org/doi/10.1021/acsomega.0c01942?goto=supporting-info).^1^H, ^13^C, and ^31^P NMR, HRMS, and 2-D ^1^H--^31^P HMBC spectra for **5**, **6**, and **9** and LC spectra of ADU-S100 incubated with svPDE and nP1 ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.0c01942/suppl_file/ao0c01942_si_001.pdf))
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